Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They needed that win, whatcha got on the go????
Sorry i got back to late, few good ones on the go yesterday, lets see what tommorrow brings.
SKH....could return back up as to where it used to be!!!
SKH....coming back up!
Good morning $brich$, EEGC bid's firming up.....
The assault on EEGC lining up!
Sweet....once EEGC cracks into the .04's it'll then get interesting!
EEGC .038 x .0395 2/1 +10 points!
EEGC should see the .04's by mid day, how you been?
I wonder who's plate is 'octopus Paul' is going to land on for supper??????
SKH looking solid!
Nice movement north on SBRH!
Few more bidders on EEGC then she's gone!
Morning VZ3, EEGC good for a few points!
DCTH....green as can be!
OWVI had itself a nice little run....got any othersÉ
Nice chart on XTXI, came across TSYS
Thank God the weekend is here....
TSYS moving up on news!
SBRH .0055 x .0058 +29 points, .0072 HOD
UWRL Looking good today.
Then you'll like BWEN, could get back over $4
Morning, UWRL sweet looking!
ELCR (good volume) >>>> Electric Car Company, Inc. Awarded Contract to Build Limobuses for Don Brown Bus Sales
2010-07-06 09:00 ET - News Release
SPRINGFIELD, Mo., July 6, 2010 (GLOBE NEWSWIRE) -- Electric Car Company, Inc. (OTCBB:ELCR), a vehicle conversion Company that specializes in electric conversions and manufacturing for the Livery and Fleet Markets, announced today that it has been awarded a 12 month contract with Don Brown Bus Sales, Inc. The Contract, valued at $750,000.00, calls for Electric Car Company, (ECC), to convert up to twenty-five (25) Federal Coach bus chassis into Imperial Coach limobuses. The Company plans to deliver the first two buses by mid-August of this year.
It was reported in LCT magazine in January of this year that the Federal Coach Bus line manufacturer out of Goshen, Indiana, is no longer producing limousine-style interiors for its buses. Federal is now concentrating solely on shuttles and mass-transit style buses. This has created a vacuum in the limobus sector for the chauffeured transportation industry, one that Electric Car Company has been poised to exploit.
The Company will facilitate the conversions of the buses through its wholly owned subsidiary, Imperial Coach Works, Inc., and its custom manufacturing division, Imperial Coach Builders, Inc. Imperial Coach is well known to be one of the premier designers of limobus interiors in the United States. The company is very excited to be given this vote of confidence by Don Brown Bus Sales, the exclusive dealer of Federal Coach Buses in the Northeastern United States.
Take a look at SNMN news>>> SNM Global Executes to Acquire $49 Million Portfolio and Prepares for International Distribution
2010-07-06 08:30 ET - News Release
LONDON -- (MARKET WIRE) -- 07/06/10
SNM Global Holdings (PINKSHEETS: SNMN) announced the signing of a Letter of Intent (LOI) with EQ-ip Equities (EQ-ip), a private technology and licensing holding company, to acquire, develop, distribute, and commercialize certain technologies from its portfolio.
With the signing of this LOI, the company officially launches its new operations and expansion. Final agreements will be timely completed and executed with appropriate announcements and disclosures made. Further sector-specific additions to the company's portfolio will be announced as they are completed.
EQ-ip specializes in clean energy technologies and solutions for emerging economies. Its portfolio of nascent and commercial technologies and Intellectual Property are currently valued in excess of $49,000,000.
The Agreement calls for the Company to acquire, develop and commercialize the EQ-ip technologies and Intellectual Property through its pioneering MicroTechnology Transfer Program (mt2) and MicroEquity Partner Program. The assets, technologies, and solutions will be introduced into SNM Global's distribution network for emerging market insertion and introduction.
And a good morning to you....u must've ran out of fireworks!!!!
Great news, you would expect the volume on EEGC to continue....
Morning...have a good long weekend?
CORX >>>> Cortex Receives Funding from The Michael J. Fox Foundation to Discover Drug Candidates for Parkinson’s Disease
2010-07-06 09:17 ET - News Release
Company Website: http://www.cortexpharm.com
IRVINE, Calif. -- (Business Wire)
Cortex Pharmaceuticals, Inc. (OTCBB: CORX) announced that it has been awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to test selected compounds from its AMPAKINE® platform for their ability to restore brain function in animal models of Parkinson’s disease.
The award will be used to test Cortex’s selected proprietary High Impact AMPAKINE drug candidates in the mouse MPTP model of Parkinson’s disease (PD), a well-validated model that exhibits many of the hallmarks of human Parkinson’s disease and has been used extensively for drug development in PD. If successful, the work could lead to a neuroprotective treatment for PD with the potential to slow or stop the course of the disease -- something no currently available therapy has been proven to do. Current treatments for PD alleviate the symptoms but do not attack the underlying disease, or alter its course. Positive results will support moving selected compounds towards human clinical trials.
The grant was awarded under MJFF’s Therapeutics Development Initiative aimed at supporting industry preclinical development of Parkinson’s disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms above and beyond current standards of care. “The award from The Michael J. Fox Foundation for Parkinson’s Research will allow Cortex to further develop its AMPAKINE program toward the ultimate goal of finding a breakthrough treatment for Parkinson’s disease. We are excited to work side by side with the Foundation to speed discovery of therapies that will benefit the five million people living with PD worldwide,” said Mark Varney, Ph.D., President and Chief Executive Officer of Cortex.
Previous research by Cortex and its collaborators, including Professors Gary Lynch and Christine Gall from the University of California, Irvine, have demonstrated that High Impact AMPAKINE molecules stimulate the production and release of certain growth factors in the brain, including brain-derived neurotrophic factor (BDNF). BDNF is essential for maintaining cell health in the normal brain, and plays an important role in restoring function following damage to the brain. Through elevating BDNF in damaged brain regions, the High Impact AMPAKINE compounds may restore function to previously damaged areas, and ameliorate PD symptoms. Additional details, including the investigators, title and abstract of the funded project may be found on the Michael J Fox Foundation website at: http://www.michaeljfox.org/research_MJFFfundingPortfolio_searchableAwardedGrants_3.cfm?ID=668
VCTY....tug of war between Bid Ask!
Selling has stopped, back up she will go!
THRA .0018 x .0019 3/1
OWVI>>> One World Ventures Reports Continued Strong Growth 1Q 2010
2010-06-22 09:29 ET - News Release
LAS VEGAS, NV -- (MARKET WIRE) -- 06/22/10
One World Ventures, Inc. (PINKSHEETS: OWVI) announced today that it has released on pinksheets.com financial results for its first fiscal quarter of 2010, posting an increase in net profit.
Based on the continuing strength of its growing business subsidiaries, the company successfully achieved profitability for the third consecutive quarter.
"One World Ventures has had three profitable quarters in a row," CEO Stephen Prior said. "This is quite an accomplishment considering we are still in a growth phase of the company. We anticipate continued success going forward."
CEO Stephen Prior will be featured on SmallCapVoice.com Thursday, June, 24.
Take a look at APCVZ, pharma play, should be good for a few points. News out!
AROX...ROCKS, lets see how she does here at the open.
Looks good!
APCVZ>>>> APP Pharmaceuticals Announces Approval of Ganciclovir for Injection, USP
2010-06-22 01:01 ET - News Release
SCHAUMBURG, Ill. -- (Business Wire)
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene ®-IV, which is marketed by Roche Laboratories, Inc.
APP will soon launch Ganciclovir for Injection and will package the product in single dose, 500 mg vials. APP's Ganciclovir for Injection is AP-rated, latex-free and bar-coded. According to IMS Health, sales of this product for 2009 in the United States were approximately $13.5 million1.
Ganciclovir for Injection is an antiviral drug, which is used in the treatment of Cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), as well as for the prevention of CMV disease in transplant recipients at risk for CMV disease. CMV disease is a serious illness that can lead to blindness, transplant graft loss and potential loss of life.
“This approval reinforces APP’s commitment to provide our customers, and the patients they treat, with a consistently expanding portfolio of products,” said John Ducker, president and chief executive officer of APP Pharmaceuticals. “The addition of Ganciclovir for Injection further strengthens APP’s broad anti-infective portfolio and market leadership position.”
News on acquisition around the corner as per their news release!
AROX, thin .0099 +182 points
Send out one of those Psychic e-mails to the mm's to move out of the way!!!